Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer

Experimental and Therapeutic Medicine

Volumn 2, Issue 6, 2011, Pages 1177-1181

  Liu, Yongping ^a   Ling, Yang ^a   Qi, Qiufeng ^a   Tang, Yexin ^a   Xu, Jianzhong ^a   Zhou, Tong ^a   Sheng, Guifeng ^a   Yang, Quanliang ^a   Pan, Yaodong ^a  

^a China   (China)

Author keywords

Chemotherapy; Gastric cancer; Objective response; Survival; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; THYMIDINE KINASE 1;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; STOMACH CANCER; TREATMENT RESPONSE;

EID: 80052726229     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.338     Document Type: Article

References (18)

1. Leung WK, Wu MS, Kakugawa Y, et al: Screening for gastric cancer Asia: current evidence practice. Lancet Oncol 9: 279-287, 2008.
2. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities reduce cancer disparities different geographic regions the world. J Clin Oncol 24: 2137-2150, 2006.
3. Macdonald JS: Treatment localized gastric cancer. Semin Oncol 31: 566-573, 2004.
4. Wagner AD, Unverzagt S, Grothe W, et al: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev CD004064, 2010.
5. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
6. Xu XH, Zhang YM, Shu XH, et al: Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy. Mol Med Rep 1: 705-711, 2008.
7. Paesmans M, Sculier JP, Libert P, et al: Response chemotherapy has predictive value for further survival with advanced non-small cell lung cancer: 10 years experience the European Lung Cancer Working Party. Eur J Cancer 33: 2326-2332, 1997.
8. Ke PY and Chang ZF: Mitotic degradation of human thymidine kinase 1 is dependent on anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol 24: 514-526, 2004.
9. He Q, Mao Y, Wu J, et al: Cytosolic thymidine kinase is a specific histopathologic tumour marker breast carcinomas. Int J Oncol 25: 945-953, 2004.
10. O'Neill KL, Buckwalter MR and Murray BK: Thymidine kinase: diagnostic prognostic potential. Expert Rev Mol Diagn 1: 428-433, 2001.
11. He Q, Zou L, Zhang PA, Lui JX, Skog S and Fornander T: The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. Int J Biol Markers 15: 139-146, 2000.
12. Zou L, Zhang PG, Zou S, Li Y He Q: The half-life of thymidine kinase 1 serum measured by ECL dot blot: a potential marker for monitoring the response to surgery patients with gastric cancer. Int J Biol Markers 17: 135-140, 2002.
13. Chen Y, Ying M, Hu M, et al: Serum 1 correlates clinical stages and clinical reactions monitors outcome of therapy 1,247 cancer patients in routine clinical settings. Int J Clin Oncol 15: 359-368, 2010.
14. He Q, Fornander T, Johansson H, et al: Thymidine kinase 1 serum predicts increased risk distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res 26: 4753-4759, 2006.
15. Kallander CF, Simonsson B, Hagberg H and Gronowitz JS: Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer 54: 2450-2455, 1984.
16. Hallek M, Langenmayer I, Nerl C, et al: Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 93: 1732-1737, 1999.
17. Hallek M, Wanders L, Ostwald M, et al: Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 22: 439-447, 1996.
18. Magnac C, Porcher R, Davi F, et al: Predictive value serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia 17: 133-137, 2003.